Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Depreciation & Amortization (CF) (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed Depreciation & Amortization (CF) for 3 consecutive years, with $564000.0 as the latest value for Q4 2025.

  • Quarterly Depreciation & Amortization (CF) fell 18.14% to $564000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.5 million through Dec 2025, up 8.71% year-over-year, with the annual reading at $2.5 million for FY2025, 8.67% up from the prior year.
  • Depreciation & Amortization (CF) for Q4 2025 was $564000.0 at Inhibrx Biosciences, down from $582000.0 in the prior quarter.
  • The five-year high for Depreciation & Amortization (CF) was $760000.0 in Q3 2024, with the low at $295000.0 in Q2 2023.
  • Average Depreciation & Amortization (CF) over 3 years is $514909.1, with a median of $564000.0 recorded in 2025.
  • The sharpest move saw Depreciation & Amortization (CF) soared 150.0% in 2024, then dropped 23.42% in 2025.
  • Over 3 years, Depreciation & Amortization (CF) stood at $298000.0 in 2023, then surged by 131.21% to $689000.0 in 2024, then fell by 18.14% to $564000.0 in 2025.
  • According to Business Quant data, Depreciation & Amortization (CF) over the past three periods came in at $564000.0, $582000.0, and $662000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.